Teva Pharmaceuticals (TEVA)

• Market cap: $24.8B
• 1 day: 1.11%
• 5 days: 4.63%
• 1 month: 4.98%
• 3 months: 22.05%
• 6 months: 33.82%
• Year to date: 2.91%
• 1 year: 98.73%
• 5 years: 114.90%
• 10 years: -62.49%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 37,851

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

207% more call options, than puts

Call options by funds: $575M | Put options by funds: $187M

25% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 59

12% more funds holding in top 10

Funds holding in top 10: 25 [Q2] → 28 (+3) [Q3]

10% more capital invested

Capital invested by funds: $10.2B [Q2] → $11.3B (+$1.07B) [Q3]

1% more funds holding

Funds holding: 525 [Q2] → 531 (+6) [Q3]

10% more repeat investments, than reductions

Existing positions increased: 189 | Existing positions reduced: 172

0.77% more ownership

Funds ownership: 55.51% [Q2] → 56.28% (+0.77%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18 18% downside
• Avg. target: $25 16% upside
• High target: $30 37% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Piper Sandler David Amsellem 58% 1-year accuracy 23 / 40 met price target	37% upside $30	Overweight Maintained	17 Jan 2025
Barclays Balaji Prasad 47% 1-year accuracy 21 / 45 met price target	28% upside $28	Overweight Maintained	18 Dec 2024
JP Morgan Chris Schott 24% 1-year accuracy 4 / 17 met price target	18% downside $18	Neutral Maintained	21 Oct 2024